GlycoNex Competitors and Similar CompaniesClear all
GlycoNex's competitors and similar companies include CytomX Therapeutics, Oncopeptides, Heidelberg Pharma and Taiho Oncology.
 GlycoNex GlycoNex (台灣醣聯生技醫藥股) is a company developing cancer drugs utilizing glycosphingolipid antigen and human monoclonal antibody technologies. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Heidelberg Pharma Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. |  Taiho Oncology Taiho Oncology is a pharmaceutical company engaged in the discovery and development of cancer treatments. | ||
Founding Date | Founding Date 2001 | Founding Date 2008 | Founding Date 2000 | Founding Date 1997 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations TW HQ | Locations South San Francisco, US HQ | Locations Stockholm, SE HQ Stockholm, SE Los Altos, US Mountain View, US Waltham, US | Locations Ladenburg, DE HQ Ladenburg, DE | Locations Singapore, SG HQ Oakville, CA Chiyoda City, JP Birmingham, GB Menlo Park, US Princeton, US |
Employees | Employees N/A | Employees 15815% increase | Employees 80 | Employees 60 | Employees 4191% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 78 m | Valuation ($) 42.4 m | Valuation ($) 158.3 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$37.9m (FY, 2025) | Revenue (est.) $76.2m (FY, 2025) | Revenue (est.) kr71.1m (FY, 2025) | Revenue (est.) €1.5m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods NT$14.3m (FY, 2025) | Cost of goods N/A | Cost of goods kr2.5m (FY, 2025) | Cost of goods (€2.5m) (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit NT$36.7m (FY, 2025) | Gross profit N/A | Gross profit kr72m (FY, 2025) | Gross profit €6.3m (FY, 2025) | Gross profit N/A |
Net income | Net income (NT$235.2m) (FY, 2025) | Net income ($17.4m) (FY, 2025) | Net income (kr249.6m) (FY, 2025) | Net income (€42.3m) (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
CytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View company
Oncopeptides
HQ
Stockholm, SE
Employees
80
Oncopeptides is a clinical development pharmaceutical company.
View companyHeidelberg Pharma
HQ
Ladenburg, DE
Employees
60
Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
View companyTaiho Oncology
HQ
Singapore, SG
Taiho Oncology is a pharmaceutical company engaged in the discovery and development of cancer treatments.
View company